

Q2 and Half Year Results 2008

30 July 2008
Analyst & Investor Conference Call




Profit & Loss: Key Figures (in million Euro)

	Q2 '07	Q2 '08	% change (excl. curr.)	H1 '07	H1 '08	% change (excl. curr.)
Sales	845	777	-8.1% (-2.6%)	1,631	1,530	-6.2% (-1.2%)
Gross profit	304	252	-17.1%	606	510	-15.8%
as a % of sales	36.0%	32.4%		37.2%	33.3%	
R&D	-47	-47	0.0%	-94	-95	1.1%
SG&A*	-196	-171	-12.8%	-388	-337	-13.1%
as a % of sales	23.2%	22.0%		23.8%	22.0%	
Other operating items*	-7	4		-12	1	
Recurring EBITDA*	89	67	-24.7%	183	138	-24.6%
as a % of sales	10.5%	8.6%		11.2%	9.0%	
Recurring EBIT*	55	38	-30.9%	113	79	-30.1%
as a % of sales	6.5%	4.9%		6.9%	5.2%	

* Before restructuring charges and non-recurring items.

- ➔ Sales decline in Q2 due to strong Euro (47 million Euro) and economic slowdown in US and UK
- ➔ Gross profit impacted by 18 million Euro higher raw material costs in Q2
- ➔ Continued strong SG&A reduction in all business groups


Net Financial Debt (in million Euro)




➔ Target to decrease net financial debt by end of year to level below 650 million Euro

Working Capital: Key Figures (in million Euro/days)


Inventories



Trade Receivables



Trade Payables



Main Drivers behind Key Figures

Q2 2008


- Sales at 777 million Euro – decrease of 2.6% (in local currency) due to strong Euro and economic slowdown in US and UK
- Margins impacted by 18 million Euro higher raw material costs (mainly silver)
- Decrease of SG&A costs with 25 million Euro (of which 6 million currency impact) due to continued efforts to improve efficiency
- Recurring EBIT at 38 million Euro – Net result at 3 million Euro
- Net financial debt at 737 million Euro versus 809 million Euro in the second quarter of 2007

Profit & Loss: Key Figures (in million Euro)

	Q2 '07	Q2 '08	% change	H1 '07	H1 '08	% change
Recurring EBIT*	55	38	-30.9%	113	79	-30.1%
Restructuring and non-recurring	-13	-11		-21	-16	
Operating result	42	27	-35.7%	92	63	-31.5%
Non-operating result	-19	-21		-19	-42	
Profit before taxes	23	6	-73.9%	73	21	-71.2%
Taxes and minority interest	19	-3		11	-8	
Net result	42	3	-92.9%	83	13	-84.3%

* Before restructuring charges and non-recurring items.

Agfa Graphics



Graphics: Key Figures (in million Euro)

	Q2 '07	Q2 '08	% change (excl. curr.)	H1 '07	H1 '08	% change (excl. curr.)
Sales	411	385	-6.3% (-0.5%)	801	763	-4.7% (0.5%)
Gross profit	126	117	-7.1%	259	240	-7.3%
as a % of sales	30.7%	30.4%		32.3%	31.5%	
R&D	-20	-17	-15.0%	-40	-35	-12.5%
SG&A*	-92	-87	-5.4%	-180	-167	-7.2%
as a % of sales	22.4%	22.6%		22.5%	21.9%	
Other operating items*	1	1		-6	-7	
Recurring EBITDA*	29.7	25.7	-13.5%	64.7	56.9	-12.1%
as a % of sales	7.2%	6.7%		8.1%	7.5%	
Recurring EBIT*	14.7	13.7	-6.8%	32.7	30.9	-5.5%
as a % of sales	3.6%	3.6%		4.1%	4.1%	


* Before restructuring charges and non-recurring items.

➔ Stable sales excluding currency effect

➔ 8 million Euro impact of raw material costs offset by continued focus on cost savings

Graphics: YTD Sales per Business Segment

YTD 2008
100% = 763 million Euro




Graphics: Main Drivers behind Key Figures

Q2 2008

- Stable sales in local currency despite economic slowdown in US and UK and related pricing pressure
 - Continued growth in digital plates more than offset decline of analog business
 - Successful introduction of finalized first generation inkjet at drupa
 - No effect yet from aluminium and energy clauses, which will be gradually added to plate contracts
- Gross profit impacted by 8 million Euro higher raw material costs
- Lower SG&A costs despite additional marketing expenses for drupa
- Prepress EBIT margin approximately 6% of sales, impacted by drupa (~3 million Euro) and write-down of receivables (~1 million Euro)
- Decrease of inkjet losses in line with plan

Agfa HealthCare




HealthCare: Key Figures (in million Euro)

	Q2 '07	Q2 '08	% change (excl. curr.)	H1 '07	H1 '08	% change (excl. curr.)
Sales	365	313	-14.3% (-8.4%)	699	607	-13.2% (-8.0%)
Gross profit	161	121	-24.8%	311	240	-22.8%
as a % of sales	44.1%	38.7%		44.5%	39.5%	
R&D	-26	-27	3.9%	-52	-55	5.8%
SG&A*	-96	-78	-18.8%	-192	-155	-19.3%
as a % of sales	26.3%	24.9%		27.5%	25.5%	
Other operating items*	-6	4		-7	7	
Recurring EBITDA*	50.3	34.5	-31.4%	95.3	66.7	-30.0%
as a % of sales	13.8%	11.0%		13.6%	11.0%	
Recurring EBIT*	33.3	19.5	-41.4%	60.3	36.7	-39.1%
as a % of sales	9.1%	6.2%		8.6%	6.1%	

* Before restructuring charges and non-recurring items.

- ➔ Sales decline mainly driven by impact of strong Euro on competitive position and market decline in US and UK
- ➔ Significant SG&A reduction not able to compensate sales decline and mix effects

HealthCare: YTD Sales per Business Segment




* Includes Radiology and Cardiology IT

HealthCare: Main Drivers behind Key Figures

Q2 2008

- Weakness in US and UK markets
- Sales decrease in local currency mainly driven by impact of strong Euro on competitive position, especially in US and UK
 - Market driven decline of classical film
 - Good performance of CR/Modalities
 - Recovery of PACS sales compared to Q1 but impact of NHS contract in Q2'07
 - HIS/CIS -> focus on France
- Good momentum in emerging countries
- Continued significant reduction of SG&A costs (-18.8%)
- EBIT affected by silver costs (7 million Euro), sales decline and unfavorable mix effects

Agfa Materials



Materials: Pro Forma Sales

(in million Euro)	Q2 '07	Q2 '08	H1 '07	H1 '08
Internal sales*	125	117	238	220
Specialty Products	69	79	131	160
TOTAL	194	196	369	380

* Sales to Agfa Graphics and Agfa HealthCare

Specialty Products: Key Figures (in million Euro)

	Q2 '07	Q2 '08	% change (excl. curr.)	H1 '07	H1 '08	% change (excl. curr.)
Sales	69	79	14.5% (16.3%)	131	160	22.1% (23.9%)
Gross profit	17	13	-23.5%	37	29	-21.6%
as a % of sales	24.6%	16.5%		28.2%	18.1%	
R&D	-1	-3	200.0%	-2	-5	150.0%
SG&A*	-8	-7	-12.5%	-15	-14	-6.7%
as a % of sales	11.6%	8.9%		11.5%	8.8%	
Other operating items*	1	2		0	2	
Recurring EBITDA*	11.3	6.8	-39.8%	23.7	14.7	-38.0%
as a % of sales	16.4%	8.6%		18.1%	9.2%	
Recurring EBIT*	9.3	4.8	-48.4%	20.7	11.7	-43.5%
as a % of sales	13.5%	6.1%		15.8%	7.3%	

* Before restructuring charges and non-recurring items.

- ➔ Sales increase driven by large contracts and by silver clauses
- ➔ Profitability negatively impacted by mix effects, silver price and increased development for new products

Specialty Products: Main Drivers behind Key Figures

Q2 2008

- Sales increase of 16.3% in local currency
 - Mainly driven by large volume contracts in Film Manufacturing Services, including silver clauses
 - Market-driven declining trend in some traditional products, such as cine film
- Impact of raw materials (3 million Euro)
- Additional R&D expenses for new products such as membranes and synthetic paper
- Profitability negatively impacted by mix effect, silver price, R&D for new products and stock depreciation (2 million Euro)

Outlook

- Graphics
 - Stable sales in prepress in 2008
 - Inkjet planned to reach break-even in the course of 2009
- HealthCare
 - Stronger IT revenues expected in second half 2008
 - Digital technology will not offset decline in traditional film and print business
- Specialty Products
 - Strengthening its position as leading supplier in traditional film markets
 - Focus on new growth markets to compensate for market-driven decline in traditional business
- Continued focus on reduction of SG&A costs.
- Target to reduce financial debt to level below 650 million Euro

Questions & Answers

